Newly published details of a pre-planned, six-month interim analysis of a Phase II trial with Takeda Pharmaceutical Co. Ltd.'s dengue candidate vaccine TAK-003 show the tetravalent product elicited a broad antibody response against all four viral serotypes, regardless of previous infection.
The findings with the live-attenuated product in the ongoing DEN-204 trial, which recruited 1,794 participants aged 2-17 in dengue-endemic areas,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)